FDA and Biogen discussed Aduhelm's accelerated approval as early as 2019 — report
Top FDA neuroscience official Billy Dunn has been a vocal advocate for Biogen and its Alzheimer’s drug Aduhelm throughout the entire review process all the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
